Suppression of B-cell proliferation to lipopolysaccharide is mediated through induction of the nitric oxide pathway by tumor necrosis factor-α in mice with acute graft-versus-host disease

Blood

Volumn 87, Issue 7, 1996, Pages 2853-2860

  Falzarano, Giorgio ^b   Krenger, Werner ^a   Snyder, Kurt M ^b   Delmonte Jr , John ^b   Karandikar, Mahesh ^b   Ferrara, James L M ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPOLYSACCHARIDE; N(G) METHYLARGININE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

EID: 0029998994     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.7.2853.bloodjournal8772853     Document Type: Article

References (62)

1. Rolink AG, Gleichmann E: Allosuppressor- and allohelper-T cells in acute and chronic graft-versus-host (GVH) disease. III. Different Lyt subsets of donor T cells induce different pathological syndromes. J Exp Med 158:546, 1983
2. Gleichmann E, Pals ST, Rolink AG, Radaskiewicz T, Gleichmann H: Graft-versus-host reactions: Clues to the etiopathology of a spectrum of immunological diseases. Immunol Today 5:324, 1984
3. Xenocostas A, Lapp WAS, Osmond DG: Suppression of B lymphocyte genesis in the bone marrow by systemic graft-versus-host reactions. Transplantation 43:549, 1987
4. Hakim FT, Shearer GM: Immunologic and hematopoietic deficiencies of graft-versus-host disease, in Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY, Dekker, 1990, p 133
5. Wall DA, Hamberg SD, Reynolds DS, Burakoff SJ, Abbas AK, Ferrara JLM: Immunodeficiency in graft-versus-host reaction. I. Mechanism of immune suppression. J Immunol 140:2970, 1988
6. Nathan C, Xie Q: Nitric oxide synthases: Roles, tolls and controls. Cell 78:915, 1994
7. Langrehr JM, Dull KE, Ochoa JB, Billiar TR, Ildstad ST, Schraut WH, Simmons RL, Hoffman RA: Evidence that nitric oxide production by in vivo allosensitized cells inhibits the development of allospecific CTL. Transplantation 53:632, 1992
8. Hoffman RA, Langrehr JM, Billiar TR, Curran RD, Simmons RL: Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J Immunol 145:2220, 1990
9. Albina JE, Abate JA, Henry WL: Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. Role of IFN-γ in the induction of the nitric oxide synthesizing pathway. J Immunol 147:144, 1991
10. Denham S, Rowland IJ: Inhibition of the reactive proliferation of lymphocytes by activated macrophages: The role of nitric oxide. Clin Exp Immunol 87:157, 1992
11. Fu Y, Blankenhorn EP: Nitric oxide-induced anti-mitogenic effects in high and low responder rat strains. J Immunol 148:2217, 1992
12. Langrehr JM, Hoffman RA, Lancaster JR Jr, Simmons RL: Nitric oxide - A new endogenous immunomodulator. Transplantation 55:1205, 1993
13. Stuehr DJ, Nathan CF: Nitric oxide: A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169:1543, 1989
14. Hoffman RA, Langrehr JM, Wren SM, Dull KE, Ildstad ST, McCarthy SA, Simmons RL: Characterization of the immunosuppressive effects of nitric oxide in graft vs host disease. J Immunol 151:1508, 1993
15. Langrehr JM, Murase N, Markus PM, Cai X, Neuhaus P, Schraut W, Simmons RL, Hoffmann RA: Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. J Clin Invest 90:679, 1992
16. Garside P, Hutton AK, Severn A, Liew FY, Mowat AM: Nitric oxide mediates intestinal pathology in graft-vs-host disease. Eur J Immunol 22:2141, 1992
17. Ding AH, Nathan CF, Stuehr DJ: Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol 141:2407, 1988
18. Drapier JC, Weitzerbin J, Hibbs JB: Interferon-γ and tumor necrosis factor induce the L-arginine dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 18:1587, 1988
19. Hoffmann RA, Langrehr JM, Dull KE, McCarthy SA, Jordan ML, Simmons RL: Macrophage synthesis of nitric oxide in the mouse mixed lymphocyte reaction. Transplant Immunol 2:313, 1994
20. Ferrara JLM : Cytokine dysregulation as a mechanism of graft-versus-host disease. Curr Opin Immunol 5:794, 1993
21. Piguet PF: Tumor necrosis factor and graft-versus-host disease, in Burakoff SJ, Deeg HJ, Ferrara JLM, Atkinson K (eds): Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY, Dekker, 1990, p 255
22. Nestel FP, Price KS, Seemayer TA, Lapp WS: Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 175:405, 1992
23. Holler E, Kolb HJ, Moeller A, Kempeni J, Liesenfeld S, Pechumer H, Lehmacher W, Ruckdeschel G, Gleixner B, Riedner C, Ledderose G, Brehm G, Mittermueller J, Wilmanns W: Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75:1011, 1990
24. Holler E, Kolb HJ, Hintermeier-Knabe R, Mittermueller J, Thierfelde S, Kaul M, Wilmanns W: The role of tumor necrosis factor-α in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 25:1234, 1993
25. Korngold R, Sprent J: T cell subsets in graft-vs.-host disease, in Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY, Dekker, 1990, p 31
26. Ferrara JLM, Burakoff SJ: The pathophysiology of acute graft-vs-host disease in a murine bone marrow transplant model, in Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-vs.-Host Disease: Immunology, Pathophysiology, and Treatment. New York, NY, Dekker, 1990, p 9
27. Coffman RL, Weissman IL: A monoclonal antibody that recognizes B cells and B cell precursors in mice. J Exp Med 153:269, 1981
28. Springer TA: Monoclonal antibody analysis of complex biological systems. Combination of cell hybridization and immunoadsorbents in a novel cascade procedure and its application to the macrophage cell surface. J Biol Chem 256:3833, 1981
29. Nassif X, Mathison JC, Wolfson E, Koziol JA, Ulevitch RJ, So M: Tumor necrosis factor-α antibody protects against lethal meningococcaemia. Mol Microbiol 6:591, 1992
30. Krenger W, Snyder K, Smith S, Ferrara JLM: Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 58:1251, 1994
31. Hibbs JB, Vavrin Z, Taintor RR: L-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 138:550, 1987
32. Unkeless JC: Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 150:580, 1979
33. 15N]nitrate in biological fluids. Anal Biochem 126:131, 1982
34. Coffman B: Surface antigen expression and immunoglobulin rearrangement during mouse pre-B cell development. Immunol Rev 69:5, 1982
35. Ferrara JLM: The cytokine storm of acute graft-versus-host disease. Haematol Rev 8:27, 1994
36. Mills CD: Molecular basis of "suppressor" macrophages: Arginine metabolism via the nitric oxide synthase pathway. J Immunol 146:2719, 1991
37. + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 155:585, 1995
38. Troutt AB, Kelso A: Enumeration of lymphokine mRNA-containing cells in vivo in a murine graft-versus-host reaction using the PCR. Proc Natl Acad Sci USA 89:5276, 1992
39. Allen RD, Staley TA, Sidman CL: Differential cytokine expression in acute and chronic murine graft-versus-host disease. Eur J Immunol 23:333, 1993
40. + T cells activated in a graft-versus-host reaction. J Immunol 145:2167, 1990
41. 40a. Krenger W, Snyder KM, Delmonte J Jr, Byon JCH, Falzarano G, Ferrara JLM: Interferon-γ and tumor necrosis factor-a mediate immunodeficiency after allogeneic bone marrow transplantation through induction of the nitric oxide pathway. Blood 86:624a, 1995 (abstr, suppl 1)
42. Piguet PF, Grau GE, Allet B, Vassalli PJ: Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease. J Exp Med 166:1280, 1987
43. Piguet PF, Grau GE, Collart MA, Vassalli P, Kapanci Y: Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor mRNA and chronic interstitial pneumonitis. Lab Invest 61:37, 1989
44. McCarthy PL, Abhyankar S, Neben S, Newman G, Sieff C, Thompson RC, Burakoff SJ, Ferrara JLM: Inhibition of interleukin-1 by an interleukin-1 receptor antagonist prevents graft-versus-host disease. Blood 78:1915, 1991
45. Jadus MR, Wepsic HT: The role of cytokines in graft-versus-host reactions and disease. Bone Marrow Transplant 10:1, 1992
46. Parkman R, Lenarsky C, Barrantes B, Santos R, Weinberg K: Cytokines versus cytotoxic T lymphocytes (CTL) in the pathogenesis of acute graft-versus-host disease (GVHD). J Cell Biochem 16a:186, 1992
47. Hoffmann RA, Langrehr JM, Simmons RL: Induction of nitric oxide synthesis during the immune response, in Ildstad ST (ed): Chimerism and Tolerance. Austin, TX, R.G. Landes Co, 1995, p 79
48. Albina JE, Henry WL: Suppression of lymphocyte proliferation through the nitric oxide synthesizing pathway. J Surg Res 50:403, 1991
49. Shearer GM, Polisson RP: Mutual recognition of parental and F1 lymphocytes. Selective abrogation of cytotoxic potential of F1 lymphocytes by parental lymphocytes. J Exp Med 151:20, 1980
50. Fecho K, Maslonek KA, Coussons-Read ME, Dykstra LA, Lysle DT: Macrophage-derived nitric oxide is involved in the depressed concanavalin A responsiveness of splenic lymphocytes from rats administered morphine in vivo. J Immunol 152:5845, 1994
51. Ikarashi Y, Kawai K, Watanabe H, Matsumoto Y, Omata S, Fujiwara M: Immunosuppressive activity of macrophages in mice undergoing graft-versus-host reaction due to major histocompatibility complex class I plus II difference. Immunology 79:95, 1993
52. Holda JH, Maier T, Claman HN: Natural suppressor activity in graft-vs-host spleen and normal bone marrow is augmented by IL-2 and interferon-γ. J Immunol 137:3538, 1986
53. Palathumpat V, Dejbakhsh-Jones S, Holm B, Strober S: Different subsets of T cell in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease. J Immunol 149:808, 1992
54. Angulo I, Rodriguez R, Garcia B, Medina M, Navarro J, Subiza JL: Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-γ. J Immunol 155:15, 1995
55. Klimpel GR, Annable CR, Cleveland MG, Jerrels TR, Patterson JC: Immunosuppression and lymphoid hypoplasia associated with chronic graft-versus-host disease is dependent upon IFN-γ production. J Immunol 144:84, 1990
56. Wall DA, Sheehan KC: The role of tumor necrosis factor-α and interferon-γ in graft-versus-host disease and related immunodeficiency. Transplantation 57:273, 1994
57. Huchet R, Bruley-Rosset M, Mathiot C, Grandjon D, HallePannenko O: Involvement of IFN-γ and transforming growth factor-β in graft-vs-host reaction-associated immunosuppression. J Immunol 150:2517, 1993
58. Holda JH, Maier T, Claman NH: Evidence that IFN-γ is responsible for natural suppressor activity in GVHD spleen and normal bone marrow. Transplantation 45:772, 1988
59. Drobyski WR, Keever CA, Hanson GA, McAuliffe T, Griffith OW: Inhibition of nitric oxide production is associated with enhanced weight loss, decreased survival, and impaired alloengraftment in mice undergoing graft-versus-host disease after bone marrow transplantation. Blood 84:2363, 1994
60. Genaro AM, Hortelano S, Alvarez A, Martinez C, Bosca L: Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained bcl-2 levels. J Clin Invest 95:1884, 1995
61. Mannick JB, Asano K, Izumi K, Kieff E, Stamler JS: Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 79:1137, 1994
62. Xie K, Huang S, Dong Z, Juang SH, Gutman M, Xie QW, Nathan C, Fidler IJ: Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 181:1333, 1995